<DOC>
	<DOCNO>NCT03000348</DOCNO>
	<brief_summary>This study investigate use cysteamine treatment adult Cystic Fibrosis experience exacerbation CF-associated lung disease . There six different potential dosing regimen , include one placebo .</brief_summary>
	<brief_title>A Study Dosing , Efficacy , Safety Oral Cysteamine Adult Patients With Cystic Fibrosis Exacerbations</brief_title>
	<detailed_description>This multicenter , double-blind , randomize , placebo-controlled , 6-arm study investigate optimal dose regimen , efficacy , safety cysteamine treatment adult patient CF experience exacerbation CF-associated lung disease . Patients screen study eligible patient randomize receive either cysteamine placebo add-on therapy standard care treatment CF-associated lung disease .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Cysteamine</mesh_term>
	<criteria>1 . CFassociated lung disease document history chronic infection Gramnegative organism ( ) 2 . Established patient Principal Investigator 's CF Multi Disciplinary Team ( MDT ) 3 . Age ≥18 year 4 . Weight &gt; 40 kg 5 . FEV1 &gt; 30 % predict within 6 month prior study exacerbation 6 . At baseline visit : experience new exacerbation CFassociated lung disease ( base Investigator assessment ≥4 symptom present Fuchs ' criterion ) require treatment include aminoglycoside antibiotic 7 . Women childbearing potential ( surgically sterile 2 year postmenopausal ) men female partner childbearing potential must use medically accept method contraception must agree continue use method duration study 30 day participation study . Acceptable method contraception men woman include abstinence , barrier method ( condom diaphragm ) spermicide , intrauterine device ( IUD ) , vasectomy conjunction barrier method , steroidal contraceptive ( oral , transdermal , implanted , inject ) conjunction barrier method . 8 . Willing able comply protocol requirement procedure , include induction sputum , necessary 9 . Willing able provide sign date informed consent 1 . Hypersensitive cysteamine excipients 2 . Hypersensitive penicillamine 3 . Transplant recipient 4 . Participation interventional clinical research study ( participation observational study exclusionary ) within 30 day Baseline ( Day 0 ) , plan participation interventional clinical research study duration study 5 . If female , pregnancy , plan pregnancy , breastfeed 6 . Any significant disease/disorder , Investigator 's opinion , either put patient risk due study participation , may influence result study patient 's ability participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Exacerbation</keyword>
	<keyword>CF</keyword>
	<keyword>Lung disease</keyword>
	<keyword>Lung infection</keyword>
	<keyword>Gram negative</keyword>
	<keyword>Bacterial Infection</keyword>
	<keyword>pneumonia</keyword>
	<keyword>bronchitis</keyword>
</DOC>